Kira Pharma
Christina Weng has worked in the medical field since 2019. Christina began their career as Co-Founder of MYMIEL Skincare in 2019. In 2020, they took on the role of Dermatologist at Massachusetts General Hospital and Instructor in Dermatology at Harvard Medical School. In 2021, they became Senior Medical Director & BD/IR and Medical Director at Kira Pharmaceuticals. In 2022, they were appointed to the Conference Board of Directors at Dermatology Summit and the Board of Directors at Dermatology Innovation Forum.
Christina Weng completed their education history with a Bachelor of Science from Caltech, followed by an MD from Harvard Medical School. Christina then completed a Postdoctoral Fellowship at Harvard University, and finally a Harvard Combined Dermatology Training Program as a Resident in Dermatology.
Kira Pharma
Kira Pharmaceuticals is a global biotechnology company pioneering a new generation of complement-targeted therapies to treat immune-mediated diseases. Enabled by its proprietary LOGIC drug discovery platform, Kira is committed to advancing first-in-class and best-in-class therapies to patients around the world. The company is headquartered in Cambridge, Massachusetts with an R&D center in Suzhou, China.